VITO Health, Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium.
Department of Growth and Reproduction, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark.
Int J Environ Res Public Health. 2022 Jun 1;19(11):6787. doi: 10.3390/ijerph19116787.
Human biomonitoring has become a pivotal tool for supporting chemicals' policies. It provides information on real-life human exposures and is increasingly used to prioritize chemicals of health concern and to evaluate the success of chemical policies. Europe has launched the ambitious REACH program in 2007 to improve the protection of human health and the environment. In October 2020 the EU commission published its new chemicals strategy for sustainability towards a toxic-free environment. The European Parliament called upon the commission to collect human biomonitoring data to support chemical's risk assessment and risk management. This manuscript describes the organization of the first HBM4EU-aligned studies that obtain comparable human biomonitoring (HBM) data of European citizens to monitor their internal exposure to environmental chemicals. The HBM4EU-aligned studies build on existing HBM capacity in Europe by aligning national or regional HBM studies. The HBM4EU-aligned studies focus on three age groups: children, teenagers, and adults. The participants are recruited between 2014 and 2021 in 11 to 12 primary sampling units that are geographically distributed across Europe. Urine samples are collected in all age groups, and blood samples are collected in children and teenagers. Auxiliary information on socio-demographics, lifestyle, health status, environment, and diet is collected using questionnaires. In total, biological samples from 3137 children aged 6-12 years are collected for the analysis of biomarkers for phthalates, HEXAMOLL DINCH, and flame retardants. Samples from 2950 teenagers aged 12-18 years are collected for the analysis of biomarkers for phthalates, Hexamoll DINCH, and per- and polyfluoroalkyl substances (PFASs), and samples from 3522 adults aged 20-39 years are collected for the analysis of cadmium, bisphenols, and metabolites of polyaromatic hydrocarbons (PAHs). The children's group consists of 50.4% boys and 49.5% girls, of which 44.1% live in cities, 29.0% live in towns/suburbs, and 26.8% live in rural areas. The teenagers' group includes 50.6% girls and 49.4% boys, with 37.7% of residents in cities, 31.2% in towns/suburbs, and 30.2% in rural areas. The adult group consists of 52.6% women and 47.4% men, 71.9% live in cities, 14.2% in towns/suburbs, and only 13.4% live in rural areas. The study population approaches the characteristics of the general European population based on age-matched EUROSTAT EU-28, 2017 data; however, individuals who obtained no to lower educational level (ISCED 0-2) are underrepresented. The data on internal human exposure to priority chemicals from this unique cohort will provide a baseline for Europe's strategy towards a non-toxic environment and challenges and recommendations to improve the sampling frame for future EU-wide HBM surveys are discussed.
人体生物监测已成为支持化学品政策的重要工具。它提供了有关实际人体接触的信息,并且越来越多地用于优先考虑对健康有影响的化学品,并评估化学品政策的成功。欧洲在 2007 年推出了雄心勃勃的 REACH 计划,以改善人类健康和环境的保护。2020 年 10 月,欧盟委员会发布了其新的可持续发展化学品战略,以实现无毒环境。欧洲议会呼吁委员会收集人体生物监测数据,以支持化学品的风险评估和风险管理。本文描述了首次与 HBM4EU 一致的研究的组织,这些研究获得了可比的欧洲公民人体生物监测(HBM)数据,以监测他们对环境化学物质的内部暴露情况。HBM4EU 一致的研究通过与国家或地区 HBM 研究相一致,利用欧洲现有的 HBM 能力。HBM4EU 一致的研究侧重于三个年龄组:儿童、青少年和成年人。参与者在 2014 年至 2021 年期间在欧洲各地的 11 至 12 个初级抽样单位招募。所有年龄组均采集尿液样本,儿童和青少年采集血液样本。使用问卷收集有关社会人口统计学、生活方式、健康状况、环境和饮食的辅助信息。共有 3137 名 6-12 岁儿童的生物样本用于分析邻苯二甲酸酯、HEXAMOLL DINCH 和阻燃剂的生物标志物。从 2950 名 12-18 岁的青少年中采集样本,用于分析邻苯二甲酸酯、HEXAMOLL DINCH 和全氟和多氟烷基物质(PFAS)的生物标志物,从 3522 名 20-39 岁的成年人中采集样本,用于分析镉、双酚和多环芳烃(PAHs)的代谢物。儿童组中,男孩占 50.4%,女孩占 49.5%,其中 44.1%居住在城市,29.0%居住在城镇/郊区,26.8%居住在农村地区。青少年组中,女孩占 50.6%,男孩占 49.4%,其中 37.7%的居民居住在城市,31.2%居住在城镇/郊区,30.2%居住在农村地区。成年组中,女性占 52.6%,男性占 47.4%,71.9%居住在城市,14.2%居住在城镇/郊区,只有 13.4%居住在农村地区。该研究人群在年龄匹配的 EUROSTAT EU-28,2017 数据基础上接近欧洲人口的特征,但代表性不足的是没有或教育程度较低(ISCED 0-2)的个体。该独特队列中有关优先化学品对人体内部暴露的数据将为欧洲迈向无毒环境的战略提供基准,并讨论了改进未来全欧盟人体生物监测调查抽样框架的挑战和建议。